The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay.
Promising red-light myopia treatment for children is raising safety concerns among experts
Myopia, or near-sightedness, is on the rise: Nearly half of the world’s population will be nearsighted by 2050, according to the World Health Organization. The condition